Live without Investor Presentation limits. August 2021 Forward Looking Statements and Industry and Market Data Unless the context otherwise requires, the terms "Trulieve," "we," "us" and "our" in this prospectus refer to

2021Exhibit 99.1 Live without Investor Presentation limits. August 2021

Forward Looking Statements and Industry and Market Data Unless the

context otherwise requires, the terms "Trulieve," "we," "us" and "our" in this prospectus refer to Trulieve Cannabis Corp. and its subsidiaries. Certain statements in this presentation constitute

forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation (collectively herein referred to as "forward-looking statements"), which can often

be identified by words such as "will", "may", "estimate", "expect", "plan", "project", "intend", "anticipate" and other words indicating that the

statements are forward-looking. Such forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors, including, but not limited to, risk factors included in this presentation,

that could cause the Company's actual results, performance or achievements or industry results to differ materially from any future results, performance or achievements implied by such forward-looking statements. Such risks and uncertainties

include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses; engaging in activities which currently are illegal under United States federal law and the

uncertainty of existing protection from United States federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including United States state-law legalization, particularly in Florida, due to

inconsistent public opinion, perception of the medical-use and adult-use cannabis industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; reliance on management; and the

effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with

customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which

speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except

as required by applicable securities laws. Unless otherwise noted, the forecasted industry and market data contained herein are based upon management estimates and industry and market publications and surveys. The information from industry and

market publications has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. The Company has not independently verified any of the data from third-party

sources, nor has the Company ascertained the underlying economic assumptions relied upon therein. While such information is believed to be reliable for the purposes used herein, the Company makes no representation or warranty with respect to the

accuracy of such information. PLEASE NOTE: MARIJUANA IS ILLEGAL UNDER U.S. FEDERAL LAW, INCLUDING ITS CONSUMPTION, POSSESSION, CULTIVATION, DISTRIBUTION, MANUFACTURING, DISPENSING, AND POSSESSION WITH INTENT TO DISTRIBUTE. Forward-looking statements

made in this document are made only as of the date of their initial publication, and the Company undertakes no obligation to publicly update any of these forward-looking statements as actual events unfold. TRULIEVE IR PRESENTATION| AUGUST 2021

Management's Use of Non-GAAP Financial Measures Our management

uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non- GAAP financial

measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Adjusted EBITDA is a financial measure that is not defined under GAAP. Our management uses this non-GAAP

financial measure and believes it enhances an investor's understanding of our financial and operating performance from period to period because it excludes certain material non-cash items and certain other adjustments management believes are

not reflective of our ongoing operations and performance. Adjusted EBITDA excludes from net income as reported interest, share-based compensation, tax, depreciation, amortization, acquisition and transaction costs, fair value step-up of inventory

from acquisitions, non-cash expenses and other income. The financial measures noted above are metrics that have been adjusted from the GAAP net income measure in an effort to provide readers with a normalized metric in making comparisons more

meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. As noted above, our Adjusted EBITDA is not prepared in accordance with GAAP, and should

not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA rather than net income, which is the most directly comparable financial

measure calculated and presented in accordance with GAAP. Because of these limitations, we consider, and you should consider, Adjusted EBITDA together with other operating and financial performance measures presented in accordance with GAAP. A

reconciliation of Adjusted EBITDA from net income, the most directly comparable financial measure calculated in accordance with GAAP, has been included at the end of this presentation. TRULIEVE IR PRESENTATION | AUGUST 2021 3Management's Use

of Non-GAAP Financial Measures Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our

operating results. These non- GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Adjusted EBITDA is a financial measure that is not defined under

GAAP. Our management uses this non-GAAP financial measure and believes it enhances an investor's understanding of our financial and operating performance from period to period because it excludes certain material non-cash items and certain

other adjustments management believes are not reflective of our ongoing operations and performance. Adjusted EBITDA excludes from net income as reported interest, share-based compensation, tax, depreciation, amortization, acquisition and transaction

costs, fair value step-up of inventory from acquisitions, non-cash expenses and other income. The financial measures noted above are metrics that have been adjusted from the GAAP net income measure in an effort to provide readers with a normalized

metric in making comparisons more meaningful across the cannabis industry, as well as to remove non-recurring, irregular and one-time items that may otherwise distort the GAAP net income measure. As noted above, our Adjusted EBITDA is not prepared

in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA rather than net income, which is the

most directly comparable financial measure calculated and presented in accordance with GAAP. Because of these limitations, we consider, and you should consider, Adjusted EBITDA together with other operating and financial performance measures

presented in accordance with GAAP. A reconciliation of Adjusted EBITDA from net income, the most directly comparable financial measure calculated in accordance with GAAP, has been included at the end of this presentation. TRULIEVE IR PRESENTATION |

98 7 Dispensaries States (as of August 15, 2021) (including GA Notice of

Intent to Award Class 1 Production License) 14 2.2Msq ft Consecutive Cultivation quarters in US profitability (as of June 30, 2021) (through June 30, 2021)98 7 Dispensaries States (as of August 15, 2021) (including GA Notice of Intent to Award Class

1 Production License) 14 2.2Msq ft Consecutive Cultivation quarters in US profitability (as of June 30, 2021) (through June 30, 2021)

Trulieve Timeline - A History of Firsts 2015 2017 2019 2021

Expected organic growth and Won the First First to sell Filed for expansion through M&A and Medical smokable flower (and won) application processes Marijuana in Florida ability to 2016 2018 2020 Application in grandfather in WV Acquisitions CT

Acquisition Opened first Profitable since 2018 First to sell Florida 14 stores PA Acquisition dispensary and Edibles in the above the RTO on CSE served first state of Florida Florida cap Harvest Acquisition* MA Acquisition patient PA Acquisition GA

License** CA Acquisition WV License *Pending acquisition ** Notice of Intent to Award Class 1 Production License TRULIEVE IR PRESENTATION | AUGUST 2021 5Trulieve Timeline - A History of Firsts 2015 2017 2019 2021 Expected organic growth and

Won the First First to sell Filed for expansion through M&A and Medical smokable flower (and won) application processes Marijuana in Florida ability to 2016 2018 2020 Application in grandfather in WV Acquisitions CT Acquisition Opened first

Profitable since 2018 First to sell Florida 14 stores PA Acquisition dispensary and Edibles in the above the RTO on CSE served first state of Florida Florida cap Harvest Acquisition* MA Acquisition patient PA Acquisition GA License** CA Acquisition

WV License *Pending acquisition ** Notice of Intent to Award Class 1 Production License TRULIEVE IR PRESENTATION | AUGUST 2021 5

Harvest Health & Recreation Acquisition We believe the Trulieve and

Harvest combination will expand our regional hub strategy and provide leading market positions in the most attractive markets. The combination will allow us to accelerate our national expansion strategy and go deeper in the markets we operate to

support our vision of increasing access to cannabis through industry- leading retail stores, innovative high-quality products and brands and delivering optimal Cultivate customer experiences. Your PotentialHarvest Health & Recreation Acquisition

We believe the Trulieve and Harvest combination will expand our regional hub strategy and provide leading market positions in the most attractive markets. The combination will allow us to accelerate our national expansion strategy and go deeper in

the markets we operate to support our vision of increasing access to cannabis through industry- leading retail stores, innovative high-quality products and brands and delivering optimal Cultivate customer experiences. Your Potential

A Top Performing Multi-State Operator Operations Today Building our Hub

Strategy - Combined Footprint with Harvest Florida California Connecticut PA MA NORTHEAST 22 stores Pennsylvania 330K sq. ft. Massachusetts cultivation & MA production CT WV PA CT NV Under Construction CO CA MD WV MD West Virginia CA AZ AZ

AZ Georgia SOUTHWEST GA 21 stores 375K sq. ft. Expansion Coming GA cultivation & via Harvest M&A FL production CO NV FL Arizona SOUTHEAST 99 stores Colorado 2.4 M sq. ft. Maryland cultivation & + production Combined Nevada 142 Stores

3.1M sq ft Cultivation & Processing As of August 15, 2021 TRULIEVE IR PRESENTATION | AUGUST 2021 7A Top Performing Multi-State Operator Operations Today Building our Hub Strategy - Combined Footprint with Harvest Florida California

Connecticut PA MA NORTHEAST 22 stores Pennsylvania 330K sq. ft. Massachusetts cultivation & MA production CT WV PA CT NV Under Construction CO CA MD WV MD West Virginia CA AZ AZ AZ Georgia SOUTHWEST GA 21 stores 375K sq. ft. Expansion Coming GA

cultivation & via Harvest M&A FL production CO NV FL Arizona SOUTHEAST 99 stores Colorado 2.4 M sq. ft. Maryland cultivation & + production Combined Nevada 142 Stores 3.1M sq ft Cultivation & Processing As of August 15, 2021 TRULIEVE

IR PRESENTATION | AUGUST 2021 7

States Where we operate today 8 TRULIEVE IR PRESENTATION | AUGUST

2021States Where we operate today 8 TRULIEVE IR PRESENTATION | AUGUST 2021

SE HUB: Florida Original application state. Leader with number of firsts

in the state. 88 stores supported by ~2M sq ft cultivation as of August 15, 2021 Outperform with 24% stores and 46% of market share at end Q2 2021 Over 550,000 patients, or 94% of registered patients have visited a Trulieve

store State patient count grew 12% in Q2 to ~583,000 MJBiz estimates 2022 FL sales to be $1.2B - $1.4B TRULIEVE IR PRESENTATION | AUGUST 2021 9SE HUB: Florida Original application state. Leader with number of firsts in the state. 88

stores supported by ~2M sq ft cultivation as of August 15, 2021 Outperform with 24% stores and 46% of market share at end Q2 2021 Over 550,000 patients, or 94% of registered patients have visited a Trulieve store State

patient count grew 12% in Q2 to ~583,000 MJBiz estimates 2022 FL sales to be $1.2B - $1.4B TRULIEVE IR PRESENTATION | AUGUST 2021 9

SE HUB: Georgia Won application and notified of intent to award one of

two top Class I Production licenses in the state. Plan to open a cultivation and production facility in Adel, GA Will be allowed 5 dispensaries with the license 16 qualifying conditions Approximately 18,000 patients

registered in the state MJBiz estimates 2022 GA sales to be $110M-$135M TRULIEVE IR PRESENTATION| AUGUST 2021 10

NE HUB: Pennsylvania th Entered the 5 most populated and limited

license state via acquisitions of cultivation facility and dispensary portfolios. Cultivation operations in Pittsburgh - State-of-the-art cultivation & extraction facilities, expanding to meet market demand Contiguous land

available for expansion - Wholesales to 100% of the PA market 6 Stores located in two of the highest populated metro areas of Philadelphia and Pittsburgh. State patient count grew ~7% in Q2 to ~550,000 MJBiz estimates 2022 PA

sales to be $1.2B - $1.4B TRULIEVE IR PRESENTATION| AUGUST 2021 11NE HUB: Pennsylvania th Entered the 5 most populated and limited license state via acquisitions of cultivation facility and dispensary portfolios. Cultivation operations in

Pittsburgh - State-of-the-art cultivation & extraction facilities, expanding to meet market demand Contiguous land available for expansion - Wholesales to 100% of the PA market 6 Stores located in two of the highest

populated metro areas of Philadelphia and Pittsburgh. State patient count grew ~7% in Q2 to ~550,000 MJBiz estimates 2022 PA sales to be $1.2B - $1.4B TRULIEVE IR PRESENTATION| AUGUST 2021 11

NE HUB: Massachusetts Launched operations for medical and adult use at

the end of Q2 2021. 140K sq ft cultivation and production facility in Holyoke, MA 78K sq ft of cultivation and production Opened first store in June 2021 and second store in August Launching pad for new Trulieve

brands Wholesale to start in 2H21 Estimates of ~94K patients and 1.3 -1.6M consumers in the state MJBiz estimates 2022 MA Sales to be $1.4B-$1.7B TRULIEVE IR PRESENTATION| AUGUST 2021 12NE HUB: Massachusetts Launched operations for

medical and adult use at the end of Q2 2021. 140K sq ft cultivation and production facility in Holyoke, MA 78K sq ft of cultivation and production Opened first store in June 2021 and second store in August Launching

pad for new Trulieve brands Wholesale to start in 2H21 Estimates of ~94K patients and 1.3 -1.6M consumers in the state MJBiz estimates 2022 MA Sales to be $1.4B-$1.7B TRULIEVE IR PRESENTATION| AUGUST 2021 12

NE HUB: Connecticut Latest state to approve adult use with plans to

roll out in 2022. Acquisition of The Healing Corner in Bristol, CT in 2019 Rebranded to Trulieve Q1 2020 Outperforms as one of 18 dispensaries in the state, yet serves approximately 9% of medical patient population

State registry grew ~4% in Q2 to ~54,000 patients MJBiz estimates 2022 CT sales to be $170M-$210M (Estimate prior to legalization in June 2021) TRULIEVE IR PRESENTATION| AUGUST 2021 13NE HUB: Connecticut Latest state to approve adult use with plans

to roll out in 2022. Acquisition of The Healing Corner in Bristol, CT in 2019 Rebranded to Trulieve Q1 2020 Outperforms as one of 18 dispensaries in the state, yet serves approximately 9% of medical patient population

State registry grew ~4% in Q2 to ~54,000 patients MJBiz estimates 2022 CT sales to be $170M-$210M (Estimate prior to legalization in June 2021) TRULIEVE IR PRESENTATION| AUGUST 2021 13

NE HUB: West Virginia Entered state through processor and dispensary

application wins. Broadened reach in the state and created a vertical with the acquisition of cultivation and dispensaries licenses First to commence operations in the state and get plants in ground in July 2020 Creates a

vertical operation in a well-located, low-cost state ready for future developments 2,300 registered patients as of June 2021 MJBiz estimates 2022 WV sales to be $5M-$6M TRULIEVE IR PRESENTATION| AUGUST 2021 14NE HUB: West Virginia Entered

state through processor and dispensary application wins. Broadened reach in the state and created a vertical with the acquisition of cultivation and dispensaries licenses First to commence operations in the state and get plants in

ground in July 2020 Creates a vertical operation in a well-located, low-cost state ready for future developments 2,300 registered patients as of June 2021 MJBiz estimates 2022 WV sales to be $5M-$6M TRULIEVE IR PRESENTATION| AUGUST

SW HUB: California This location is used for research & development

to gain insights into west coast brands. Acquisition of Leef Industries Dispensary in Palm Springs, California Opened in May 2018 Licensed medical/adult-use cannabis dispensary Estimates of 6-7M consumers in

the state MJBiz estimates 2022 CA sales to be $5.3B-$6.2B TRULIEVE IR PRESENTATION| AUGUST 2021 15SW HUB: California This location is used for research & development to gain insights into west coast brands. Acquisition of Leef Industries

Dispensary in Palm Springs, California Opened in May 2018 Licensed medical/adult-use cannabis dispensary Estimates of 6-7M consumers in the state MJBiz estimates 2022 CA sales to be $5.3B-$6.2B TRULIEVE IR

PRESENTATION| AUGUST 2021 15

Brands Opportunity for all consumers to live their best life Brands

Opportunity for all consumers to live their best life

Our new brand portfolio In addition to our Trulieve branded portfolio,

we recently launched a new family of products: Cultivar Muse Sweet Talk Momenta Collection You know you Unlock what Empower your Crafted for an Elevated want some is within wellness journey Experience Craveable confections The Muse product line

Committed to doing the A premium group of small- infused with high-quality awakens creativity, giving best by your body each batch, top-shelf cannabis. cannabis, the taste of you permission to let go and every day, to Each unique strain is hand-